FUSE: Study of Posterior Cervical Stabilization System (PCSS) as Part of Circumferential Fusion to Treat Multilevel DDD

Sponsor
Providence Medical Technology, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04229017
Collaborator
(none)
330
17
2
44.5
19.4
0.4

Study Details

Study Description

Brief Summary

This study will evaluate the safety and effectiveness of a device called "Posterior Cervical Stabilization System or PCSS" when used along with posterior cervical fusion (PCF) in combination with anterior cervical discectomy and fusion (ACDF) in the treatment of multi-level cervical degenerative disease.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Anterior Cervical Discectomy and Fusion
  • Device: Posterior Cervical Stabilization System (PCSS)
N/A

Detailed Description

Degenerative disc disease (DDD) is a condition in which people experience pain because of compression on the spinal cord or nerve roots caused by degenerating cervical discs. Discs sit between the bones of the spine to provide cushioning, shock absorption, mobility, and load-bearing. When the discs break down, the space between the bones gets smaller and squeezes on the spinal cord or nerve roots causing radiating pain down the neck, shoulders, or arms.

A surgical approach to address cervical (neck) DDD is to fuse the bones together to prevent further compression. This can be done with or without removing the disc material itself. The most common way to perform a cervical spinal (neck) fusion to address DDD is to come in from the front of the neck, decompress the spine to relieve pain, and fuse the bones together to prevent further pain in a procedure called Anterior Cervical Discectomy and Fusion (ACDF). Another option is to come in from the back of the neck in a procedure called Posterior Cervical Fusion (PCF). Sometimes these procedures are combined to provide further decompression and stability in the bones of the neck to promote fusion leading to quicker pain relief and return to function.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
330 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
prospective, randomized, controlled multi-center trialprospective, randomized, controlled multi-center trial
Masking:
Single (Participant)
Masking Description:
Patients will be randomly assigned to either the treatment or control arms at 1:1 ratio.
Primary Purpose:
Treatment
Official Title:
Safety and Effectiveness of Posterior Cervical Stabilization System (PCSS) as an Adjunct to Posterior Cervical Fusion, When Used in Combination With ACDF in Treatment of Multi-level Cervical Degenerative Disease
Actual Study Start Date :
Mar 18, 2020
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Anterior Cervical Discectomy and Fusion (ACDF)

ACDF is a a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate. The plate is intended to stabilize the treated levels until fusion occurs.

Procedure: Anterior Cervical Discectomy and Fusion
Anterior Cervical Decompression and Fusion (ACDF) is a standard of care procedure that is performed using standard instruments and completed with an allograft interbody implant and anterior plate.
Other Names:
  • ACDF
  • Experimental: Circumferential Cervical Fusion (CCF)

    Circumferential Cervical Fusion (CCF) is a combination of ACDF and Posterior Cervical Fusion (PCF) procedures. The PCF is completed with Posterior Cervical Stabilization System (PCSS).

    Device: Posterior Cervical Stabilization System (PCSS)
    Posterior Cervical Stabilization System (PCSS) is non-segmental instrumentation with integrated screw fixation intended to provide immobilization and stabilization of spinal segments. PCSS achieves bilateral facet fixation by spanning the interspace at each level with points of fixation at each end of the construct.

    Outcome Measures

    Primary Outcome Measures

    1. Superiority in Fusion Success in CCF (treatment) compared to ACDF (control) [12 months]

      An individual subject is considered a fusion success if there is evidence of bridging trabecular bone across endplates and < 2° total angular motion

    Secondary Outcome Measures

    1. Non-inferiority Composite Safety Success in CCF (treatment) compared to ACDF (control) [24 months]

      An individual subject is considered a success if all of the following safety criteria are met: Fusion success - as defined by evidence of bridging trabecular bone across endplates and < 2° total angular motion Improvement in Neck Disability Index (NDI) Improvement in Neurological function Absence of secondary surgical interventions (SSI)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 80 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. Age 18-80 years (Skeletally Mature)

    2. Indicated for ACDF treatment of degenerative disc disease (DDD) between and including C3-C7 at 3 contiguous levels

    3. NDI Score of ≥15/50

    4. Unresponsive to non-operative, conservative treatment (rest, heat, electrotherapy, physical therapy, chiropractic care and/or analgesics)

    5. Reported to be medically cleared for surgery

    6. Physically and mentally able and willing to comply with the Protocol, including the ability to read and complete required forms and willing and able to adhere to the scheduled follow-up visits and requirements of the Protocol.

    7. Written informed consent provided by subject

    Exclusion Criteria:
    1. Body Mass Index (BMI) greater than 40 kg/m2

    2. Active systemic infection or infection at the operative site

    3. History of or anticipated treatment for active systemic infection, including HIV or Hepatitis C

    4. Previous trauma to the C3 to C7 levels resulting in significant bony or disco- ligamentous cervical spine injury that may prevent device placements

    5. A prior spine surgery or pseudoarthrosis at the operative levels

    6. Axial neck pain in the absence of other symptoms of radiculopathy or myeloradiculopathy justifying the need for surgical intervention

    7. Symptomatic DDD or significant cervical spondylosis at more than three levels

    8. Diagnosis of spondylolisthesis, grade >2

    9. Overt (Segmental) instability measured as a movement on dynamic flex/ext x-rays >3.5 mm

    10. Congenital bony and/or spinal cord abnormalities that affect spinal stability

    11. Diagnosis of Paget's disease, osteomalacia or any other metabolic bone disease other than osteoporosis

    12. Osteoporosis, defined as either the SCORE or MORES ≥ 6 and a DEXA bone density measured T-score of ≤ -2.5

    13. Active malignancy or a history of any invasive malignancy (except non-melanoma skin cancer), unless treated with curative intent and without clinical signs or symptoms of the malignancy for at least five years

    14. Has an uncontrolled seizure disorder

    15. Use of epidural steroids within 14 days prior to surgery

    16. A concomitant condition requiring daily, high-dose oral and/or inhaled steroids

    17. Known allergy to titanium (Ti).

    18. Fixed or permanent neurologic deficit related to the target treatment levels that cannot be improved with surgical decompression

    19. Has, in the Investigator's opinion, any disease or condition that would preclude accurate clinical evaluation (e.g. neuromuscular disorders).

    20. Is pregnant or nursing at time of screening, or with plans to become pregnant within the next three years.

    21. A current or recent history (≤ 1 year prior to screening) of substance abuse (alcoholism and/or narcotic addiction) that required treatment.

    22. Long term use (>6 months) of opioids (max. daily amount=120 mg morphine equivalents).

    23. A mental illness or belongs to a vulnerable population, as determined by the investigator (e.g., prisoner or developmentally disabled), that would compromise ability to provide informed consent or compliance with follow-up requirements.

    24. Any other condition or anatomy (e.g. fused facet) that makes posterior fusion treatment infeasible

    25. Use of any other investigational drug or medical device within the last 30 days prior to surgery.

    26. A pending personal litigation relating to spinal injury (worker's compensation is not exclusionary).

    27. Anticipated or potential relocation greater than 50 miles that may interfere with completion of follow-up examinations.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Barrow Neurological Institute Phoenix Arizona United States 85013
    2 Scripps Encinitas California United States 92024
    3 OrthoNorCal Los Gatos California United States 95032
    4 Spine Colorado Durango Colorado United States 81301
    5 Rush University Medical Center Chicago Illinois United States 60612
    6 The Orthopaedic Institute Paducah Kentucky United States 42001
    7 Bone and Joint Clinic of Baton Rouge Baton Rouge Louisiana United States 70808
    8 LSU Health New Orleans Louisiana United States 70112
    9 Spine Institute of Louisiana Shreveport Louisiana United States 71101
    10 LifeBridge Health - Sinai Hospital of Baltimore Baltimore Maryland United States 21215
    11 Beaumont Health Royal Oak Michigan United States 48073
    12 Inspira Health Network Vineland New Jersey United States 08361
    13 The University of North Carolina at Chapel Hill Chapel Hill North Carolina United States 27599
    14 Pinehurst Surgical Clinic Pinehurst North Carolina United States 28374
    15 Atlantic Neurosurgical & Spine Specialists Wilmington North Carolina United States 28401
    16 Thomas Jefferson University Philadelphia Pennsylvania United States 19107
    17 Baylor College of Medicine Houston Texas United States 77030

    Sponsors and Collaborators

    • Providence Medical Technology, Inc.

    Investigators

    • Study Director: Victoria Sumners, Providence Medical Technology, Inc.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Providence Medical Technology, Inc.
    ClinicalTrials.gov Identifier:
    NCT04229017
    Other Study ID Numbers:
    • PMT0003
    First Posted:
    Jan 14, 2020
    Last Update Posted:
    Apr 19, 2022
    Last Verified:
    Apr 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    Yes
    Keywords provided by Providence Medical Technology, Inc.
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Apr 19, 2022